2-(methylthio)-3,4-dihydroquinazoline hydroiodide | 52147-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(methylthio)-3,4-dihydroquinazoline hydroiodide
• 英文别名: 2-(methylthio)-3,4-dihydroquinazoline hydriodide；2-methylsulfanyl-3,4-dihydro-quinazoline hydroiodide；2-(Methylsulfanyl)-3,4-dihydroquinazolin-1-ium iodide；2-methylsulfanyl-1,4-dihydroquinazolin-3-ium;iodide
• CAS: 52147-11-2
• 化学式: C₉H₁₀N₂S*HI
• mdl: MFCD18083082
• 分子量: 306.17
• InChiKey: CUDKDZJMXDONQR-UHFFFAOYSA-N

物化性质

• 熔点：
  215 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.49
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(methylthio)-3,4-dihydroquinazoline hydroiodide 在 ammonium acetate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 2-amino-3,4-dihydroquinazoline
  参考文献：
  名称：

  Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR

  摘要：

  Basic molecular building blocks such as benzene rings, amidines, guanidines, and amino groups have been combined in a systematic way to generate ligand candidates for HIV-1 TAR RNA. Ranking of the resulting compounds was achieved in a fluorimetric Tat-TAR competition assay. Although simple molecules such as phenylguanidine are inactive, few iteration steps led to a set of ligands with IC50 values ranging from 40 to 150 mu M. 1,7-Diaminoisoquinoline 17 and 2,4,6-triaminoquinazoline 22 have been further characterized by NMR titrations with TAR RNA. Compound 22 is bound to TAR at two high affinity sites and shows slow exchange between the free ligand and the RNA complex. These results encourage investigations of dimeric ligands built from two copies of compound 22 or related heterocycles. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.004
• 作为产物：
  描述：

  2-氨基苄胺 在 三乙胺 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 0.75h， 生成 2-(methylthio)-3,4-dihydroquinazoline hydroiodide
  参考文献：
  名称：

  Synthesis and adrenergic blocking effects of 2-(alkylamino)-3,4-dihydroquinazolines

  摘要：

  Based on the known biological activity of a variety of guanidine-containing agents, several N-substituted 3,4-dihydroquinazolines were synthesized. These compounds can be considered to be rigid analogues of phenylguanidines. In anesthetized rats the compounds decreased blood pressure and were antagonists of the pressor response to norepinephrine.

  DOI：

  10.1021/jm00185a026

文献信息

• (3,4-Dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine
  申请人：Alanine Alexander

  公开号：US20060252779A1

  公开（公告）日：2006-11-09

  The present invention relates to compounds of formula I wherein R, R 1 , R 2 , R 3 , R 4 , aryl, n, and m are as defined in the specification and pharmaceutically acceptable acid addition salts and tautomeric forms thereof. Such compounds have good activity on the 5-HT 5A receptor. Therefore, the invention provides methods for the treatment of certain CNS disorders with such compounds.

  本发明涉及具有以下结构的化合物，其中R、R1、R2、R3、R4、芳基、n和m如规范中定义，以及其药用可接受的酸盐和互变异构体形式。这些化合物在5-HT5A受体上具有良好的活性。因此，本发明提供了利用这些化合物治疗某些中枢神经系统疾病的方法。
• (3,4-Dihydro-quinazolin-2-yl)-indan-1-yl-amines
  申请人：Alanine Alexander

  公开号：US20060229323A1

  公开（公告）日：2006-10-12

  The present invention relates to compounds of formula wherein R 1 , R 2 , and n are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I have a good activity on the 5-HT 5A receptor. Therefore, the invention provides the use of a compound of formula I for 5-HT 5A receptor related diseases, such as anxiety, depression, sleep disorders and schizophrenia.

  本发明涉及以下式的化合物，其中R1、R2和n如本文所定义，并且其药用酸盐是可接受的。式I的化合物对5-HT5A受体有良好的活性。因此，本发明提供了使用式I的化合物用于5-HT5A受体相关疾病，如焦虑、抑郁、睡眠障碍和精神分裂症。
• (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
  申请人：Hoffmann-La Rochse Inc.

  公开号：US07348332B2

  公开（公告）日：2008-03-25

  The present invention relates to compounds of formula wherein R1, R2, and n are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I have a good activity on the 5-HT5A receptor. Therefore, the invention provides the use of a compound of formula I for 5-HT5A receptor related diseases, such as anxiety, depression, sleep disorders and schizophrenia.

  本发明涉及式I的化合物，其中R1、R2和n的定义如本文所述，并且其药物可接受的酸加盐。式I的化合物在5-HT5A受体上具有良好的活性。因此，本发明提供了将式I的化合物用于5-HT5A受体相关疾病，如焦虑、抑郁、睡眠障碍和精神分裂症的用途。
• (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine
  申请人：Hoffmann-La Roche Inc.

  公开号：US07781441B2

  公开（公告）日：2010-08-24

  The present invention relates to compounds of formula I wherein R, R1, R2, R3, R4, aryl, n, and m are as defined in the specification and pharmaceutically acceptable acid addition salts and tautomeric forms thereof. Such compounds have good activity on the 5-HT5A receptor. Therefore, the invention provides methods for the treatment of certain CNS disorders with such compounds.

  本发明涉及公式I的化合物，其中R、R1、R2、R3、R4、芳基、n和m如规范中所定义，并且其药学上可接受的酸加盐和互变异构体形式。这些化合物对5-HT5A受体具有良好的活性。因此，本发明提供了使用这些化合物治疗某些中枢神经系统疾病的方法。
• GROSSO J. A.; NICHOLS D. E.; NICHOLS M. B.; YIM G. K. W., J. MED. CHEM., 1980, 23, NO 11, 1261-1264
  作者：GROSSO J. A.、 NICHOLS D. E.、 NICHOLS M. B.、 YIM G. K. W.

  DOI：——

  日期：——